Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B (STOP-B)

G

Göteborg University

Status

Not yet enrolling

Conditions

Hepatitis B, Chronic

Treatments

Other: Stopping

Study type

Interventional

Funder types

Other

Identifiers

NCT05328427
STOP-B

Details and patient eligibility

About

Cirrhosis or cancer of the liver caused by hepatitis B virus (HBV) are major global health problems. Chronic HBV infection has become more common in Sweden with immigration. The risk of cancer and the availability of effective antivirals has led to more and more people receiving long-term treatment with antiviral drugs. The disadvantages of this treatment are that it does not have a defined duration and that it very rarely leads to the cure. Several published studies suggest that a large proportion of patients who discontinue antiviral therapy after at least three years may achieve lasting cure of the infection or at least do not need to resume treatment. The mechanism of this effect is not known, but it is thought to be due to the fact that the immune response, which is activated when the amount of virus increases after the end of treatment, becomes more effective in eradicating infected liver cells than it was before starting treatment. As a consequence of these findings updated guidelines for treatment of hepatitis B state that for patients that have received nucleoside analogue treatment for \> 3 years, discontinuation is an accepted therapeutic alternative. The purpose of the planned study is to investigate the results of discontinued treatment, in terms of clinical outcome as well as immunological and virological mechanisms. The aim is to include 120 patients at four regional infectious diseases clinics (in Gothenburg, Borås, Skövde and Trollhättan), of which 90 will be randomized to discontinue and 30 to continue antiviral treatment. Blood samples will be taken regularly to monitor the outcome and for detailed studies of viral antigens and nucleic acid in the blood and for specific analyzes of the cells of the immune system. The goal is to understand why the discontinued treatment in some patients activates an effective immune response and how such an effect can be predicted even before or early after the treatment is stopped.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Nucleoside analogue treatment for HBeAg-negative chronic hepatitis B for at least 36 months.

Exclusion criteria

  • Liver cirrhosis or liver cancer.
  • Co-infection with HCV, HDV or HIV.
  • Inability to understand study information and give informed consent

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

120 participants in 2 patient groups

Stopping
Active Comparator group
Description:
Discontinuation of nucleoside analogue treatment
Treatment:
Other: Stopping
Continue
No Intervention group
Description:
Treatment with nucleoside analogue continued

Trial contacts and locations

1

Loading...

Central trial contact

Johan Ringlander, MD; Magnus Lindh, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems